{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:36:07Z","timestamp":1794281767830,"version":"4.9.0"},"reference-count":196,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005627","name":"Universit\u00e9 de Li\u00e8ge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005627","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00762","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T06:19:48Z","timestamp":1588832388000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":83,"title":["Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies"],"prefix":"10.3389","volume":"11","author":[{"given":"Margaux","family":"Lejeune","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat Cem","family":"K\u00f6se","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Duray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Beguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Caers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/316354a0","article-title":"Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody.","volume":"316","author":"Perez","year":"1985","journal-title":"Nature."},{"key":"B2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/scd.1.1995.4.433","article-title":"Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies.","volume":"4","author":"De Gast","year":"1995","journal-title":"J Hematother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial.","volume":"127","author":"Heiss","year":"2010","journal-title":"Int J Cancer."},{"key":"B4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies.","author":"Spiess","year":"2015","journal-title":"Mol Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia.","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies.","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs."},{"key":"B7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/14712598.2019.1604672","article-title":"Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs.","volume":"19","author":"Foster","year":"2019","journal-title":"Expert Opin Biol Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","article-title":"Bispecific antibody based therapeutics: strengths and challenges.","volume":"32","author":"Thakur","year":"2018","journal-title":"Blood Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng Des Sel."},{"key":"B10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"\u201cKnobs-into-holes\u201d engineering of antibody CH3 domains for heavy chain heterodimerization.","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng."},{"key":"B11","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab.","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies.","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov Today."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.2147\/IJN.S164542","article-title":"Site-specific PEGylation of an anti-CEA\/CD3 bispecific antibody improves its antitumor efficacy.","volume":"13","author":"Pan","year":"2018","journal-title":"Int J Nanomedicine."},{"key":"B14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/07388551.2013.834293","article-title":"Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics.","volume":"35","author":"Rath","year":"2015","journal-title":"Crit Rev Biotechnol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"25612","DOI":"10.1074\/jbc.M109.027078","article-title":"Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives.","volume":"284","author":"Stork","year":"2009","journal-title":"J Biol Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1074\/jbc.M111.311522","article-title":"Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains.","volume":"287","author":"Hutt","year":"2012","journal-title":"J Biol Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline.","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"B18","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1007\/s00262-007-0333-0","article-title":"Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells.","volume":"56","author":"Tita-Nwa","year":"2007","journal-title":"Cancer Immunol Immunother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia."},{"key":"B20","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.2015.64.9970","article-title":"Bispecific T-Cell engagers (BiTEs) as treatment of B-cell lymphoma.","volume":"34","author":"Smits","year":"2016","journal-title":"J Clin Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1517\/14712598.2015.1041373","article-title":"Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.","volume":"15","author":"Stieglmaier","year":"2015","journal-title":"Expert Opin Biol Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.","volume":"321","author":"Bargou","year":"2008","journal-title":"Science."},{"key":"B23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00230","article-title":"Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies.","volume":"6","author":"Pittari","year":"2015","journal-title":"Front Immunol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00122","article-title":"Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity.","volume":"5","author":"Chretien","year":"2014","journal-title":"Front Immunol."},{"key":"B27","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.4049\/jimmunol.143.10.3283","article-title":"Natural killer cell and granulocyte Fc gamma receptor III (CD16) differ in membrane anchor and signal transduction.","volume":"143","author":"Selvaraj","year":"1989","journal-title":"J Immunol."},{"key":"B28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/sj.leu.2404499","article-title":"CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases.","volume":"21","author":"Grzywacz","year":"2007","journal-title":"Leukemia."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","article-title":"NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17).","volume":"121","author":"Romee","year":"2013","journal-title":"Blood."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cell.2019.04.041","article-title":"Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity.","volume":"177","author":"Gauthier","year":"2019","journal-title":"Cell."},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.232.232","article-title":"Trispecific killer engagers (TriKEs) that contain IL-15 to make NK cells antigen specific and to sustain their persistence and expansion.","volume":"126","author":"Miller","year":"2015","journal-title":"Blood."},{"key":"B32","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.4049\/jimmunol.1501657","article-title":"Landscape of tumor antigens in T cell immunotherapy.","volume":"195","author":"Ilyas","year":"2015","journal-title":"J Immunol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174233","article-title":"Immunotherapy-based targeting and elimination of leukemic stem cells in AML and CML.","volume":"20","author":"Valent","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00262-010-0844-y","article-title":"Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.","volume":"59","author":"Bluemel","year":"2010","journal-title":"Cancer Immunol Immunother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing.","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell."},{"key":"B36","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cpt.1396","article-title":"Bispecific antibodies in the treatment of hematologic malignancies.","volume":"106","author":"Duell","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.mayocp.2016.09.010","article-title":"Adult acute lymphoblastic leukemia.","volume":"91","author":"Paul","year":"2016","journal-title":"Mayo Clin Proc."},{"key":"B38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1365-2141.2010.08246.x","article-title":"Prognostic factors in adult acute lymphoblastic leukaemia.","volume":"150","author":"Rowe","year":"2010","journal-title":"Br J Haematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013.","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2014.073","article-title":"Diagnosis and subclassification of acute lymphoblastic leukemia.","volume":"6","author":"Chiaretti","year":"2014","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.humimm.2019.01.011","article-title":"Immunotherapy in pediatric B-cell acute lymphoblastic leukemia.","volume":"80","author":"Wyatt","year":"2019","journal-title":"Hum Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/asheducation-2013.1.612","article-title":"Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses.","volume":"2013","author":"Biondi","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?","volume":"120","author":"Pui","year":"2012","journal-title":"Blood."},{"key":"B44","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.6004\/jnccn.2015.0153","article-title":"Acute lymphoblastic leukemia, version 22015.","volume":"13","author":"Alvarnas","year":"2015","journal-title":"J Natl Compr Canc Netw."},{"key":"B45","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jconrel.2016.07.035","article-title":"Nanomedicine approaches in acute lymphoblastic leukemia.","volume":"238","author":"Tatar","year":"2016","journal-title":"J Control Release."},{"key":"B46","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","article-title":"Chronic lymphocytic leukaemia.","volume":"104","author":"Scarfo","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"key":"B47","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia.","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet (London, England)."},{"key":"B48","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","article-title":"Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/leu.2012.357","article-title":"NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.","volume":"27","author":"Villamor","year":"2013","journal-title":"Leukemia."},{"key":"B51","first-page":"24","article-title":"ATM mutations in B-cell chronic lymphocytic leukemia.","volume":"59","author":"Bullrich","year":"1999","journal-title":"Cancer Res."},{"key":"B52","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia.","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1172\/JCI64101","article-title":"Molecular pathogenesis of chronic lymphocytic leukemia.","volume":"122","author":"Gaidano","year":"2012","journal-title":"J Clin Invest."},{"key":"B54","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ccr.2009.11.019","article-title":"The DLEU2\/miR-15a\/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.","volume":"17","author":"Klein","year":"2010","journal-title":"Cancer Cell."},{"key":"B55","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines.","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood."},{"key":"B56","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.soncn.2017.05.012","article-title":"Pathobiology and diagnosis of multiple myeloma.","volume":"33","author":"Brigle","year":"2017","journal-title":"Semin Oncol Nurs."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0155-7","article-title":"Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.","volume":"8","author":"Usmani","year":"2018","journal-title":"Blood Cancer J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1634\/theoncologist.2015-0303","article-title":"the changing landscape of smoldering multiple myeloma: a European perspective.","volume":"21","author":"Caers","year":"2016","journal-title":"Oncologist."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia."},{"key":"B60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nature10909","article-title":"DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes.","volume":"484","author":"Hakim","year":"2012","journal-title":"Nature."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma.","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma.","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun."},{"key":"B64","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3324\/haematol.2018.189159","article-title":"An European myeloma network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when.","volume":"103","author":"Caers","year":"2018","journal-title":"Haematolgica."},{"key":"B65","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma.","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"B66","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma.","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group.","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol."},{"key":"B68","doi-asserted-by":"crossref","first-page":"561","DOI":"10.14694\/EDBK_175546","article-title":"Hematologic malignancies: plasma cell disorders.","volume":"37","author":"Dhodapkar","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B69","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-hodgkin lymphoma.","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet (London, England)."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network.","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer."},{"key":"B71","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.mpmed.2017.02.008","article-title":"Non-Hodgkin lymphoma.","volume":"45","author":"Ninkovic","year":"2017","journal-title":"Medicine (Baltimore)."},{"key":"B72","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.leukres.2015.11.001","article-title":"Targeting B-cell non Hodgkin lymphoma: new and old tricks.","volume":"42","author":"Solimando","year":"2016","journal-title":"Leuk Res."},{"key":"B73","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.","volume":"30","author":"Bottcher","year":"2012","journal-title":"J Clin Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.omto.2019.02.004","article-title":"Single-chain variable fragment-based bispecific antibodies: hitting two targets with one sophisticated arrow.","volume":"14","author":"Ahamadi-Fesharaki","year":"2019","journal-title":"Mol Ther Oncolytics."},{"key":"B76","doi-asserted-by":"publisher","first-page":"571","DOI":"10.4161\/mabs.21338","article-title":"CD19 as an attractive target for antibody-based therapy.","volume":"4","author":"Hammer","year":"2012","journal-title":"MAbs."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol."},{"key":"B78","first-page":"22","article-title":"BiTE: teaching antibodies to engage T-cells for cancer therapy.","volume":"11","author":"Baeuerle","year":"2009","journal-title":"Curr Opin Mol Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective.","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.","volume":"120","author":"Topp","year":"2012","journal-title":"Blood."},{"key":"B83","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA Approval: Blinatumomab.","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/CPAA.S42689","article-title":"Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia.","volume":"5","author":"Portell","year":"2013","journal-title":"Clin Pharmacol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-16-0666","article-title":"MGD011, A CD19 x CD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies.","volume":"23","author":"Liu","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1080\/19420862.2015.1029216","article-title":"A tetravalent bispecific TandAb (CD19\/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.","volume":"7","author":"Reusch","year":"2015","journal-title":"MAbs."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-160","article-title":"Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven.","volume":"11","author":"Buhmann","year":"2013","journal-title":"J Transl Med."},{"key":"B88","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1080\/10428194.2016.1272687","article-title":"Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease.","volume":"58","author":"Kieslich","year":"2017","journal-title":"Leuk Lymphoma."},{"key":"B89","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/bjh.13242","article-title":"Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.","volume":"169","author":"Schuster","year":"2015","journal-title":"Br J Haematol."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/srep17943","article-title":"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.","volume":"5","author":"Smith","year":"2015","journal-title":"Sci Rep."},{"key":"B91","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.621.621","article-title":"Phase 1 study of REGN1979, an anti-CD20 x anti-CD3 bispecific monoclonal antibody, in patients with CD20+ B-cell malignancies previously treated with CD20-directed antibody therapy.","volume":"128","author":"Bannerji","year":"2016","journal-title":"Blood."},{"key":"B92","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis Non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines.","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood."},{"key":"B93","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1836.1836","article-title":". CD20 Tcb (RG6026), a Novel \u201c2:1\u201d T Cell Bispecific Antibody for the Treatment of B Cell Malignancies.","volume":"128","author":"Bacac","year":"2016","journal-title":"Blood."},{"key":"B94","doi-asserted-by":"publisher","first-page":"728","DOI":"10.4161\/mabs.28591","article-title":"A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.","volume":"6","author":"Reusch","year":"2014","journal-title":"MAbs."},{"key":"B95","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies.","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.molmed.2008.02.005","article-title":"CD38 at the junction between prognostic marker and therapeutic target.","volume":"14","author":"Deaglio","year":"2008","journal-title":"Trends Mol Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting multiple myeloma with AMG 424, a novel Anti-CD38\/CD3 bispecific t-cell-recruiting antibody optimized for cytotoxicity and cytokine release.","volume":"25","author":"Zuch de Zafra","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B98","article-title":"Immunotherapy with long-lived Anti-CD38 \u00d7 Anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD38+ cells in monkeys: a potential therapy for acute myelogenous leukemia.","volume":"124","author":"Chu","year":"2014","journal-title":"Blood."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma.","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B101","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells.","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia."},{"key":"B103","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment.","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell."},{"key":"B104","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-122895","article-title":"First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial.","author":"Costa","year":"2019","journal-title":"Blood."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1158\/1535-7163.MCT-19-0007","article-title":"Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma.","volume":"18","author":"Panowski","year":"2019","journal-title":"Mol Cancer Ther."},{"key":"B106","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-110427","article-title":"A Phase I, open-label study to evaluate the safety, pharmacokinetic, pharmacodynamic, and clinical activity of PF-06863135, a B-cell maturation antigen\/CD3 bispecific antibody, in patients with relapsed\/refractory advanced multiple myeloma.","author":"Lesokhin","year":"2018","journal-title":"Blood."},{"key":"B107","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia.","volume":"18","author":"Polson","year":"2006","journal-title":"Int Immunol."},{"key":"B108","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/sj.leu.2404445","article-title":"Elevation of soluble CD307 (IRTA2\/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma.","volume":"21","author":"Ise","year":"2007","journal-title":"Leukemia."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","article-title":"Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma.","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol Cancer Ther."},{"key":"B110","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma.","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest."},{"key":"B111","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome.","volume":"124","author":"Lee","year":"2014","journal-title":"Blood."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax8861","article-title":"CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity.","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm.","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome.","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B115","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/MOP.0000000000000043","article-title":"Toxicity management for patients receiving novel T-cell engaging therapies.","volume":"26","author":"Barrett","year":"2014","journal-title":"Curr Opin Pediatr."},{"key":"B116","doi-asserted-by":"crossref","first-page":"14145","DOI":"10.1073\/pnas.2334336100","article-title":"Lytic versus stimulatory synapse in cytotoxic T lymphocyte\/target cell interaction: manifestation of a dual activation threshold.","volume":"100","author":"Faroudi","year":"2003","journal-title":"Proc Natl Acad Sci USA."},{"key":"B117","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.cell.2018.06.017","article-title":"Isolation of a structural mechanism for uncoupling T cell receptor signaling from peptide-MHC binding.","volume":"174","author":"Sibener","year":"2018","journal-title":"Cell."},{"key":"B118","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","article-title":"Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.","volume":"11","author":"Trinklein","year":"2019","journal-title":"MAbs."},{"key":"B119","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.blre.2014.09.012","article-title":"The double-edged sword: neurotoxicity of chemotherapy.","volume":"29","author":"Magge","year":"2015","journal-title":"Blood Rev."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-hodgkin lymphoma: final results from a phase I study.","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol."},{"key":"B121","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00262-007-0298-z","article-title":"The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19\/CD3-bispecific single-chain antibody construct.","volume":"56","author":"Brandl","year":"2007","journal-title":"Cancer Immunol Immunother."},{"key":"B122","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"key":"B123","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell."},{"key":"B124","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.","volume":"443","author":"Day","year":"2006","journal-title":"Nature."},{"key":"B125","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies.","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J."},{"key":"B126","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/leu.2013.243","article-title":"Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system.","volume":"28","author":"Arndt","year":"2014","journal-title":"Leukemia."},{"key":"B127","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/CJI.0b013e3181d75c20","article-title":"Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand\/anti-CD20 fusion proteins and anti-CD3\/anti-CD20 diabodies.","volume":"33","author":"Liu","year":"2010","journal-title":"J Immunother."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.4143\/crt.2016.491","article-title":"Engineering of Anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity.","volume":"49","author":"Schmohl","year":"2017","journal-title":"Cancer Res Treat."},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.06.012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review.","author":"Khan","year":"2019","journal-title":"Semin Cancer Biol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking.","volume":"129","author":"Braig","year":"2017","journal-title":"Blood."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy.","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/1078-0432.CCR-14-2877","article-title":"Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.","volume":"21","author":"Bachanova","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.4049\/jimmunol.1101760","article-title":"Retargeting of human regulatory T cells by single-chain bispecific antibodies.","volume":"188","author":"Koristka","year":"2012","journal-title":"J Immunol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy.","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B135","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia."},{"key":"B136","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/1389450116666150518095346","article-title":"Immunomodulatory drugs: immune checkpoint agents in acute leukemia.","volume":"18","author":"Knaus","year":"2017","journal-title":"Curr Drug Targets."},{"key":"B137","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy.","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma.","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/jjco\/hyx154","article-title":"Immune checkpoint inhibitor-related myocarditis.","volume":"48","author":"Tajiri","year":"2018","journal-title":"Jpn J Clin Oncol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"76902","DOI":"10.18632\/oncotarget.12357","article-title":"T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts.","volume":"7","author":"Feucht","year":"2016","journal-title":"Oncotarget."},{"key":"B141","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41375-018-0014-3","article-title":"Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.","volume":"32","author":"Correnti","year":"2018","journal-title":"Leukemia."},{"key":"B142","article-title":"Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 dual-affinity Re-targeting (DART\u00a7) protein with T-cell Immunomodulatory activity for cancer treatment.","author":"La Motte-Mohs","year":"2016","journal-title":"Am Assoc Cancer Res Annu Meet."},{"key":"B143","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-2776","article-title":"Abstract 2776: MEDI5752: a novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells.","author":"Dovedi","year":"2018","journal-title":"Cancer Res."},{"key":"B144","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","article-title":"CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.","volume":"20","author":"Ye","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B145","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4161\/onci.19974","article-title":"Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody.","volume":"1","author":"Houot","year":"2012","journal-title":"Oncoimmunology."},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10088-1","article-title":"Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcgammaR affinity.","volume":"10","author":"Qi","year":"2019","journal-title":"Nat Commun."},{"key":"B147","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1158\/1078-0432.CCR-17-1243","article-title":"Phase Ib study of utomilumab (PF-05082566), a 4-1BB\/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors.","volume":"23","author":"Tolcher","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an integrated safety analysis of urelumab, an agonist Anti-CD137 monoclonal antibody.","volume":"23","author":"Segal","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133647","article-title":"Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.","volume":"5","author":"Eskiocak","year":"2020","journal-title":"JCI Insight."},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01791","article-title":"Carcinoembryonic antigen (CEA)-specific 4-1BB-costimulation induced by CEA-targeted 4-1BB-agonistic trimerbodies.","volume":"10","author":"Mikkelsen","year":"2019","journal-title":"Front Immunol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-18-3654","article-title":"Tumor-localized costimulatory T-cell engagement by the 4-1BB\/HER2 bispecific antibody-anticalin fusion PRS-343.","volume":"25","author":"Hinner","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B152","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1080\/19420862.2017.1406570","article-title":"Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies.","volume":"10","author":"Van Blarcom","year":"2018","journal-title":"MAbs."},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav5989","article-title":"Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.","volume":"11","author":"Claus","year":"2019","journal-title":"Sci Transl Med."},{"key":"B154","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.","volume":"21","author":"Liu","year":"2015","journal-title":"Nat Med."},{"key":"B156","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2005-04-1463","article-title":"Species- and cell type-specific interactions between CD47 and human SIRPalpha.","volume":"107","author":"Subramanian","year":"2006","journal-title":"Blood."},{"key":"B157","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ymthe.2016.11.006","article-title":"Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies.","volume":"25","author":"Dheilly","year":"2017","journal-title":"Mol Ther."},{"key":"B158","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1386361","article-title":"CD20-selective inhibition of CD47-SIRPalpha \u201cdon\u2019t eat me\u201d signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.","volume":"7","author":"van Bommel","year":"2018","journal-title":"Oncoimmunology."},{"key":"B159","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med."},{"key":"B160","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","article-title":"Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis.","volume":"16","author":"Baker","year":"2017","journal-title":"EBioMedicine."},{"key":"B161","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/15258160151134944","article-title":"Use of anti-CD3 x anti-HER2\/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2\/neu+ tumors.","volume":"10","author":"Sen","year":"2001","journal-title":"J Hematother Stem Cell Res."},{"key":"B162","doi-asserted-by":"publisher","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies.","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B163","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ymeth.2018.11.008","article-title":"Engineering therapeutic bispecific antibodies using CrossMab technology.","volume":"154","author":"Klein","year":"2019","journal-title":"Methods."},{"key":"B164","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1080\/19420862.2016.1160192","article-title":"Development of purification processes for fully human bispecific antibodies based upon modification of protein a binding avidity.","volume":"8","author":"Tustian","year":"2016","journal-title":"MAbs."},{"key":"B165","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/protein\/gzp094","article-title":"SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.","volume":"23","author":"Davis","year":"2010","journal-title":"Protein Eng Des Sel."},{"key":"B166","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.ccell.2018.04.003","article-title":"Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 signaling via HER2-guided ligand blockade.","volume":"33","author":"Geuijen","year":"2018","journal-title":"Cancer Cell."},{"key":"B167","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1074\/jbc.M116.758862","article-title":"Recombinant expression of the full-length ectodomain of LDL receptor-related protein 1 (LRP1) unravels pH-dependent conformational changes and the stoichiometry of binding with receptor-associated protein (RAP).","volume":"292","author":"De Nardis","year":"2017","journal-title":"J Biol Chem."},{"key":"B168","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ymeth.2018.10.006","article-title":"A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.","volume":"154","author":"Moore","year":"2019","journal-title":"Methods."},{"key":"B169","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.","volume":"110","author":"Labrijn","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/ijc.23626","article-title":"Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels.","volume":"123","author":"Stanglmaier","year":"2008","journal-title":"Int J Cancer."},{"key":"B171","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.","volume":"95","author":"Loffler","year":"2000","journal-title":"Blood."},{"key":"B172","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2141.2005.05414.x","article-title":"Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).","volume":"130","author":"Bruenke","year":"2005","journal-title":"Br J Haematol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol Cancer Ther."},{"key":"B174","first-page":"115","article-title":"Enzyme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody.","volume":"4","author":"Brusselbach","year":"1999","journal-title":"Tumor Target."},{"key":"B175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS8067","article-title":"Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific T-cell engager, in relapsed and\/or refractory multiple myeloma (RRMM).","author":"Topp","year":"2016","journal-title":"J Clin Oncol."},{"key":"B176","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.09.082","article-title":"AMG 701, a half-life extended anti-BCMA BiTE\u00a7, potently induces T cell-redirected lysis of human multiple myeloma cells and can be combined with IMiDs to overcome the immunosuppressive bone marrow microenvironment.","volume":"19","author":"Cho","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B177","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.5668.5668","article-title":"Exploratory pharmacokinetic\/pharmacodynamic and tolerability study of BCMAxCD3 in cynomolgus monkeys.","volume":"128","author":"Girgis","year":"2016","journal-title":"Blood."},{"key":"B178","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112500","article-title":"REGN5458, a bispecific BCMAxCD3 T cell engaging antibody, demonstrates robust in vitro and in vivo anti-tumor efficacy in multiple myeloma models, comparable to that of BCMA CAR T Cells.","author":"Dilillo","year":"2018","journal-title":"Blood."},{"key":"B179","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.5_suppl.TPS81","article-title":"Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed\/refractory multiple myeloma.","author":"Richter","year":"2018","journal-title":"J Clin Oncol."},{"key":"B180","article-title":"Immunotherapy with long-lived Anti-CD123 \u00d7 Anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123+ cells in monkeys: a potential therapy for acute myelogenous leukemia.","volume":"124","author":"Chu","year":"2014","journal-title":"Blood."},{"key":"B181","article-title":"Complete responses in relapsed\/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of XmAb14045, a CD123 x CD3 T cell-engaging bispecific antibody: initial results of a phase 1 study.","author":"Ravandi","year":"2018","journal-title":"Blood."},{"key":"B182","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112819","article-title":"CD3-activating Bi-specific antibody targeting CD19 on B cells in Mono- and Bi-valent format.","author":"Cui","year":"2018","journal-title":"Blood."},{"key":"B183","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/hon.14_2632","article-title":"A first-in-human study of a half-life extended CD19-targeting BiTE in relapsed-refractory diffuse large B cell lymphoma, mantle cell lymphoma or follicular lymphoma.","author":"Popplewell","year":"2019","journal-title":"Hematol Oncol."},{"key":"B184","doi-asserted-by":"crossref","DOI":"10.26420\/annhematoloncol.2017.1174","article-title":"Blinatumomab induced response of multiply refractory multiple myeloma in the context of secondary Pre-B cell acute lymphoblastic leukemia.","volume":"4","author":"Pratz","year":"2017","journal-title":"Ann Hematol Oncol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1574884713666180518102514","article-title":"Pharmacokinetic and pharmacodynamic relationship of blinatumomab in patients with Non-Hodgkin lymphoma.","volume":"13","author":"Hijazi","year":"2018","journal-title":"Curr Clin Pharmacol."},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"Potent anti-tumor activity of duobody-CD3XCD20 in preclinical models in vitro and in vivo.","volume":"3","author":"Hiemstra","year":"2019","journal-title":"HemaSphere."},{"key":"B187","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/cts.12535","article-title":"A preclinical population pharmacokinetic model for Anti-CD20\/CD3 T-cell-dependent bispecific antibodies.","volume":"11","author":"Ferl","year":"2018","journal-title":"Clin Transl Sci."},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med."},{"key":"B189","article-title":"Immunotherapy with long-lived Anti-CD20 \u00d7 Anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human B cell lines and of circulating and lymphoid B cells in monkeys: a potential therapy for B cell lymphomas and leukemias.","volume":"124","author":"Chu","year":"2014","journal-title":"Blood."},{"key":"B190","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/bmt.2013.133","article-title":"Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin\u2019s lymphoma: a pilot study.","volume":"49","author":"Lum","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"B191","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.bbmt.2013.03.010","article-title":"CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin\u2019s lymphoma.","volume":"19","author":"Lum","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0188-3","article-title":"AFM13: a first-in-class tetravalent bispecific anti-CD30\/CD16A antibody for NK cell-mediated immunotherapy.","volume":"8","author":"Wu","year":"2015","journal-title":"J Hematol Oncol."},{"key":"B193","author":"Eckelman","year":"2017","journal-title":"Multivalent and Multispecific 41BB-Binding Fusion Proteins."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.leukres.2009.02.006","article-title":"Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.","volume":"33","author":"Vallera","year":"2009","journal-title":"Leuk Res."},{"key":"B195","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2554","article-title":"Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1\/CTLA4) from a first-in-human study in subjects with advanced solid tumors.","author":"Coward","year":"2019","journal-title":"J Clin Oncol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1158\/1535-7163.MCT-17-1095","article-title":"Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B-cell lymphoma and leukemia.","volume":"17","author":"Buatois","year":"2018","journal-title":"Mol Cancer Ther."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00762\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T19:34:35Z","timestamp":1696102475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00762\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":196,"alternative-id":["10.3389\/fimmu.2020.00762"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00762","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]},"article-number":"762"}}